BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trial for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in San Jose, California....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 16 May 2026
2019-07-21 09:37:00 Sunday ET

Facebook introduces a new cryptocurrency Libra as a fresh medium of exchange for e-commerce. Libra will be available to all the 2 billion active users on Fa
2019-10-13 16:22:00 Sunday ET

Apple unveils 3 iPhone 11 models with new original video services and stars such as Oprah Winfrey, Jennifer Aniston, and Reese Witherspoon. Apple releases t
2024-07-31 09:28:00 Wednesday ET

In the modern monetary system, each new CBDC helps anchor public trust in money in support of economic welfare, especially in a cashless society. In our
2019-10-07 12:35:00 Monday ET

Federal Reserve reduces the interest rate by another key quarter point to the target range of 1.75%-2% in September 2019. In accordance with the Federal Res
2017-05-19 09:39:00 Friday ET

FAMGA stands for Facebook, Apple, Microsoft, Google, and Amazon. These tech giants account for more than 15% of market capitalization of the American stock
2022-10-05 08:24:00 Wednesday ET

Precautionary-motive and agency reasons for corporate cash management Bates, Kahle, and Stulz (JF 2009) empirically find that public firms have doubled t